We speculate that nicotinic agents specifically targeted toward α7-nAChRs may be beneficial for the treatment of cerebellar ataxia [27] and autism (which has been shown to have a cerebellar component [14], [17]). The gene discussed is CHRNA7; the disease is aceruloplasminemia.